

10/708066. AEG 4/18/08

**In the Specification**

28 AEG 4/18/08  
Please amend the paragraph beginning at page 6, line 27, and ending at page 7, line 10 as follows:

The arcuate, substantially spherical outer surface 3 of the core is at least partially covered by a coating 4 having a first arcuate, substantially hemispherical, non-liquid, anterior anchoring portion 5 for attachment to a first binding structure of the orbit, such as an extraocular muscle, and a second arcuate, substantially hemispherical, non-liquid, posterior portion 6 sized and shaped to intimately fit over the outer surface of the implant. The coating has an outer surface 7 which is smoother than the outer surface 3 of the implant 2. Preferably, the anterior portion 5 is selected from a material or materials so that its bioabsorbability or degradation rate is slower than that of the posterior portion 6.

10/708000 - Aeg 4/18/08

suturing will occur, the passageways are located a distance apart from these regions. It should be understood that the passageways need not extend fully through the coating, but can be cylindrical depressions where the coating is thinner. Although, bioabsorbtion may take longer, such depressions may be more economically manufactured.

12 22 Aeg 4/18/08  
On page 13, line 1, add - - including adverse immune response reducers - - after "immuno-suppressants" as follows:

The core and coating are preferably pretreated to contain various therapeutic agents to control cell adhesion, migration, proliferation, and differentiation. Therapeutic agents can include but are not limited antibiotic agents, anti-inflammatory agents, vascularization promoting agents growth factors, cell adhesion modulating molecules, and gene fragment agents, immuno-suppressants including adverse immune response reducers, wound-healing promoters, blood-clot dissolving agents, blood-clotting agents, and any combination thereof. These compounds and conveyance vehicles are well described in Perry, U.S. Patent No. 6,248,130, incorporated herein by this reference.

11/708066- AEG 4/18/08

**In the Specification**

6 AEG 4/18/08  
On page 8, line 18, replace "attached" with - - attach - -, as follows:

The anterior portion 5 material is selected to have a degradation rate or bioabsorbability of about 6 months or longer, more preferably about one year or longer, and most preferably about 1.5 years or longer. The selected material is strong enough to hold a suture until degradation or removal of the suture, or for a period of time sufficient to allow attachment of the muscle directly to the implant through ingrowth. The coating is also sufficiently plastic to allow cutting of windows with a knife or cautery to expose the core to ~~attached~~ attach extraocular muscles. Preferably, it will allow penetration of a suturing needle interoperatively without fracturing. However, penetratability can be enhanced by providing suture holes described below. The anterior material is sufficiently rigid to maintain a sutured extraocular muscle under common tension forces directly against the implant.

10 25 AEG 4/18/08  
On page 10, line 25, add - - are - - before "located" as follows:

In order to further enhance immediate fluid flow into and out of the porous core for rapid fibrovascular ingrowth, a number of passageways 11 are manufactured into the posterior portion 6 of the coating. The passageways can be formed at the time the coating is molded or later machined into the coating after molding and/or after placement on the core. The passageways are shaped, sized and located to afford maximum fluid exchange between the core and surrounding tissues of the orbit without allowing interference from any underlying core surface spicules during implantation. The passageways are preferably uniformly spaced apart and restricted to the posterior portion 6 of the coating. Also, to maintain the structural integrity of the coating near where the extraocular muscle